FiercePharmaOriginal article
{"a":[{"_":"Kelun scores sac-TMT win in first-line NSCLC population missing from Merck’s massive phase 3 program","$":{"href":"/pharma/kelun-scores-sac-tmt-win-first-line-nsclc-population-missing-merck-massive-phase-3-program","hreflang":"en"}}]}
Phase 3positivesac-TMTPositive
AI Analysis
Summary
Kelun-Biotech achieved a positive Phase 3 result with sac-TMT in a first-line NSCLC population previously not covered in Merck's phase 3 program, potentially expanding the clinical blueprint for the TROP2-directed antibody-drug conjugate.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Kelun achieved a landmark win in first-line NSCLC population
Importance:7/10
Sentiment:
0.70
TROP2-directedantibody-drug conjugateNSCLCPhase 3Partnership
Related Companies
Read the original article
Published by FiercePharma on July 15, 2026 9:51 AM